本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
The iconic, global lifestyle brand announces multiyear partnerships with the PGA TOUR and LPGA, in addition to introducing a new golf collection to TUMI Sports' lineup NEW YORK and DAYTONA BEACH, Fla. and PONTE VEDRA BEACH, Fla., Jan. 23, 2024 /PRNewswire/ -- International travel and lifestyle brand TUMI announced multiyear partnerships with the LPGA and PGA TOUR today naming TUMI the "Official Luggage" for both organizations. TUMI's partnerships with the PGA TOUR and LPGA reinforces the brand's dedication to major global sports partnerships, such as Premier League team Tottenham Hotspur, McLaren Racing, and the Professional Tennis Players Association. TUMI's foray into golf coincides with the debut of its first full range golf collection, offering high-performance and innovative products that embody both the sport and its accompanying lifestyle. To kick off these prestigious men's and women's partnerships, TUMI is hosting an interactive booth at the PGA Show this week in Orlando, Florida, featuring product previews, influencer appearances and additional on-site programming. "We're thrilled to welcome TUMI into our PGA TOUR family alongside our partners at the LPGA," said PGA TOUR Commissioner Jay Monahan. "This collaboration with the LPGA highlights TUMI's values and our shared commitment to bettering our game by making it welcoming to all." "We are thrilled to welcome this exciting partnership with TUMI as the Official Luggage of the LPGA and the PGA TOUR," said LPGA Commissioner Mollie Marcoux Samaan. "This partnership not only signifies our shared commitment to excellence but also underscores our collective dedication to empowering women in sports around the world. As a global tour with stops in 10 countries worldwide, TUMI's innovative golf collection is a perfect match for the LPGA, and our partnership will reflect the spirit of determination, quality and style that defines both the LPGA and TUMI. We look forward to a strong collaboration between the LPGA, PGA TOUR, and TUMI, celebrating the journeys and triumphs of our athletes both on and off the course." "The PGA TOUR is excited to welcome TUMI into our family as we introduce this iconic lifestyle brand to our athletes and fans worldwide," said Brian Oliver, PGA TOUR Executive Vice President, Corporate Partnerships. "All golfers, whether casual or professional, will benefit from having access to TUMI's unique products and style as it officially enters the golf space." "We are honored to begin these partnerships with the PGA TOUR and LPGA and to celebrate the achievements of these globally esteemed athletes," said Andrew Dawson, President of TUMI. "At TUMI, we are always evolving to meet the needs and interests of our consumers and like-minded audiences. Serving our community of both competitive and leisure athletes was a deliberate yet authentic next step for our brand." Inspired by the passion of the sport and staying true to TUMI's DNA, the golf assortment delivers the brand's signature durability, high-performance materials, and innovative design. Headlining the collection are the golf bags, which offer game-enhancing features including soft-touch padding, USB-C charging ports and cooler pockets, along with monogrammable patches for an added element of personalization that is uniquely TUMI. Additional lifestyle bags and accessories spanning duffels, divot tools, tee and ball pouches, club covers and more were designed to work seamlessly together with the bag offerings. Engineered with the rigors of professional golf in mind, each piece in the collection is constructed with the highest technical detail designed to help you perform both on and off the course. The collection's golf and travel bags range from $795-$1,595 USD, with additional bags and accessories ranging from $125-$650 USD. The collection is exclusively available on TUMI.com globally and coming soon to select TUMI stores, golf clubs and select department stores this Spring. Select items will also be featured in pop-ups across the PGA TOUR and LPGA Tour tournaments globally throughout the year. To learn more about TUMI's sport partnerships, visit TUMI.com/About. About TUMI Since 1975, TUMI has been creating world-class business, travel, and performance luxury essentials, designed to upgrade, uncomplicate and beautify all aspects of life on the move. Blending flawless functionality with a spirit of ingenuity, we're committed to empowering journeys as a lifelong partner to movers and makers in pursuit of their passions. For more about TUMI, visit TUMI.com. TUMI and TUMI logo are registered trademarks of Tumi, Inc. © 2024 Tumi, Inc. About the LPGAThe Ladies Professional Golf Association (LPGA) is the world's premier women's professional golf organization. Created in 1950 by 13 pioneering female Founders, the LPGA, whose members now represent more than 60 countries, is the longest-standing professional women's sports organization. Through the LPGA Tour, the Epson Tour, the LPGA Professionals, and a joint venture with the Ladies European Tour, the LPGA provides female professionals the opportunity to pursue their dreams in the game of golf at the highest level. In addition to its professional tours and teaching accreditation programs, the LPGA features a fully integrated Foundation, which provides best-in-class programming for female golfers through its junior golf programming, and its LPGA Amateurs division, which offers its members playing and learning opportunities around the world. LPGA aims to use its unique platform to inspire, transform and advance opportunities for girls and women, on and off the golf course. Follow the LPGA online at www.LPGA.com and on its mobile apps. Join the social conversation on Facebook, X (formerly known as Twitter), Instagram and YouTube. About PGA TOURBy showcasing golf's greatest players, the PGA TOUR engages, inspires and positively impacts our fans, partners and communities worldwide. The PGA TOUR, headquartered in Ponte Vedra Beach, Florida, co-sanctions tournaments on the PGA TOUR, PGA TOUR Champions, Korn Ferry Tour, PGA TOUR Americas and administers PGA TOUR Q-School presented by Korn Ferry and PGA TOUR University. TOUR members represent the world's best players, hailing from 29 countries and territories. Showcasing the biggest moments in the sport with history and legacy on the line, the PGA TOUR has long-term domestic distribution partnerships for broadcast coverage on CBS, NBC and Golf Channel and video streaming service on ESPN+. Internationally, PGA TOUR coverage is available across 200+ countries and territories in 28 languages via 44 broadcast and digital partners. Virtually all tournaments are organized as non-profit organizations to maximize charitable giving, and to date, tournaments across all Tours have generated more than $3.64 billion. Fans can follow the PGA TOUR on the new PGA TOUR app and PGATOUR.COM, and on social media channels, including Facebook, Instagram (in Spanish, Korean and Japanese), LinkedIn, TikTok, X (in English and Spanish), WhatsApp (in English and Spanish), WeChat, Weibo, Toutiao, Douyin and LINE. TUMI Media ContactsTUMI Alexandra Gillisalexandra.gillis@tumi.com Hailey HauldrenSHADOWhhauldren@weareshadow.com LPGAJ.D. Sterbajd.sterba@lpga.com PGA TOURChris Cox chriscox@pgatourhq.com
INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is happy to announce its award-winning mobile app, IMG Mobile, is now available to all IMG customers. While previously available to select customers, all IMG customers can now use the mobile app to conveniently access their coverage and assistance services, plus manage their account from their mobile device as they currently do with the web-based customer portal, MyIMG. In November 2023, IMG Mobile was recognized for excellence in mobile app customer experience by the Travel Weekly Magellan Awards in the Online Travel Services Marketing category. "We're continually working to ensure the IMG customer experience is best-in-class, and IMG Mobile is another significant enhancement to the customer journey," said IMG Chief Commercial Officer Justin Poehler. "At IMG, our purpose is to be there to protect and enhance the well-being of our customers, and the mobile app provides our customers with the power to access and manage their account from the palm of their hands." Within IMG Mobile, customers can access their ID card and plan documents, update contact information, search provider networks, and file travel claims. Details regarding assistance services are available on the app as well. For IMG customers with Travel Intelligence access, the mobile app holds features such as location-specific risk information related to crime, terrorism, severe weather, and more. "IMG Mobile helps us to better meet the needs of our customers and contributes significantly to our overall effort of providing customers with the IMG Advantage," said IMG Chief Operating Officer Amanda Winkle. "The IMG Advantage is an all-encompassing view of how our service, strength, and safety solutions provide our customers with Global Peace of Mind. IMG Mobile further enhances our service offerings allowing us to deliver help and information when and where it's needed." Customers can download the app to their mobile device by visiting either the Google Play Store or Apple App Store. About IMG® (International Medical Group®) IMG® (International Medical Group®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG's world-class services, combined with an extensive product portfolio, provide Global Peace of Mind® for travelers, students, missionaries, marine crews, and other individuals or groups traveling, working, or living away from home. For more information, please visit www.imglobal.com.
GOTHENBURG, Sweden, Jan. 23, 2024 /PRNewswire/ -- Stena Sessan AB ('Stena Sessan'), which holds more than 90 per cent of the shares and votes in Concordia Maritime AB (publ) ('Concordia Maritime'), has requested that a compulsory buy-out of the remaining shares in Concordia Maritime be initiated. Against the above background, the Board of Directors of Concordia Maritime has decided to apply for delisting of Concordia Maritime's class B shares from Nasdaq Stockholm. The last day of trading in the class B share will be announced after Concordia Maritime has submitted the application and received a decision from Nasdaq Stockholm. The Board of Directors of Concordia Maritime has furthermore, at the request of Stena Sessan, decided to convene an Extraordinary General Meeting to be held on 22 February 2024 for resolutions on, inter alia, election of new members of the Board of Directors. The notice will be published through a separate press release. This information is information that Concordia Maritime AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the below contact persons, on 23 January 2024 at 14:00 CET. CONTACT: For more information, please contact:Stefan BrockerChairman of the Board of Directors, Concordia Maritime AB+46 709 777 687stefan.brocker@msa.se Erik LewenhauptCEO, Concordia Maritime AB+46 704 855 188erik.lewenhaupt@concordiamaritime.com The following files are available for download: https://mb.cision.com/Main/1948/3913973/2556765.pdf Concordia Maritime - Press release - Delisting - 20240123 (PDF)
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction. "We are all delighted to see CBL-514 showing its potential to become the new, promising, non-invasive fat reduction treatment in the previous Phase 2 study," said Vivian Ling, CEO of Caliway. "The following CBL-514 Phase 3 study will further investigate its fat reduction efficacy compared with placebo with the U.S. FDA-suggested fat change assessment tool, Abdominal Fat Rating Scale (AFRS) and MRI." The CBL-0301 Pivotal Phase 3 study is a multicountry and multicenter study that will recruit 300 subjects to evaluate CBL-514's efficacy, safety, and tolerability for reducing abdominal subcutaneous fat. The primary endpoint will be the percentage of subjects with at least 1-grade improvement on AFRS compared with placebo. The AFRS, developed by Caliway under the U.S. FDA recommendation, is a scale to assess fat accumulation severity and categorize subjects into 5 grades (1-5). The number indicated the severity of abdominal fat accumulation, with 1 indicating none/minimal and 5 indicating very severe. Currently, there are two CBL-514 Phase 2b studies for subcutaneous fat reduction ongoing in the U.S., Australia, and Canada. To optimize the Phase 3 study protocol and to increase its successful rate of meeting endpoints, both Phase 2b studies were designed to simulate the Phase 3 study with the same efficacy assessment tools, AFRS and MRI. Caliway will submit the final Pivotal Phase 3 study protocol as soon as the preliminary result of the CBL-0204 Phase 2b study is announced. Following up, Caliway will submit the CBL-0301 Phase 3 IND application to the U.S. FDA, EMA, and other countries' regulatory authorities. The subject recruitment will be initiated after receiving IND approval from the U.S. FDA. Caliway will also prepare to submit the IND application of another CBL-514's Pivotal CBL-0302 Phase 3 study for subcutaneous fat reduction. About CBL-0301 Pivotal Phase 3 Study The CBL-0301 Pivotal Phase 3 study is a multicountry and multicenter, randomized, double-blind, placebo-controlled study evaluating CBL-514 injection for reducing abdominal subcutaneous fat. CBL-514 will be administered via injection into the subcutaneous adipose layer on the abdomen. The study will recruit a total of 300 subjects with moderate (Grade 3) to severe (Grade 4) abdominal subcutaneous fat reduction assessed by the Abdominal Fat Rating Scale (AFRS). The subjects will be randomized in a 2:1 ratio to receive up to 4 treatments of allocated CBL-514 or placebo administered on the abdomen once every 3 weeks, and complete 3 follow-up visits 4 weeks, 8 weeks, and 12 weeks after the last treatment. The treatment dose will depend on the level of subcutaneous fat accumulation on the participant's abdomen. The maximum dose is 600 mg per treatment. The primary efficacy endpoint is the percentage of subjects with at least 1-grade AFRS improvement compared with placebo at the second follow-up. The secondary efficacy endpoints include the percentage of subjects with at least 2-grade AFRS improvement compared with placebo at each follow-up visit, and the number of treatments required to the first occurrence of 1-grade AFRS improvement. About Subcutaneous Fat Reduction The current subcutaneous fat reduction procedures include invasive surgery, such as liposuction and abdominoplasty, and non-invasive products. Studies have shown that liposuction can remove an average of 183.3mL of abdomen fat, yet it involves a lengthy procedure that is generally performed in an operating room and may also carry the risk of unfavorable outcomes and moderate to severe side effects. The efficacy of non-invasive procedures is generally less optimal with limited treatment areas and potential side effects, including tissue necrosis, nerve damage, and paradoxical adipose hyperplasia (PAH). According to the American Society of Plastic Surgeons' report, more than 60% of people are reluctant to undergo subcutaneous fat reduction procedures due to the fear of the side effects. The medical needs for subcutaneous fat reduction remain unmet. About CBL-514 CBL-514, a potentially first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. Caliway's nonclinical studies showed that CBL-514 upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 ratio, and then induces dose-dependent adipocyte apoptosis in vivo and in vitro. Caliway is investigating multiple indications for CBL-514, including non-invasive subcutaneous fat reduction, Dercum's disease, cellulite, and lipoma treatment. About Caliway Biopharmaceuticals Caliway Biopharmaceuticals (Caliway) is a Taiwan-headquartered, clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the emerging stock market in Taiwan (TPEX6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: www.Caliway.com.tw/en Disclaimer This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
Collaboration aims to transform research to improve patient outcomes and enhance the understanding of ALS and motor neuron diseases (MND) MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options. Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control. Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis. Existing treatment options solely focus on managing symptoms and providing supportive care. In the quest to uncover the elusive causes of ALS and other MNDs, where a combination of genetic and environmental factors is suspected, the integration of metabolomics becomes paramount. This collaborative effort aims to accelerate the understanding of ALS through a comprehensive biomarker approach, leveraging the power of metabolomics to deepen the understanding of ALS and serves as a unique modality that spans both internal and environmental inputs. AMBRoSIA is a Motor Neurone Disease Association (MNDA) funded longitudinal cohort of individuals from three UK tertiary ALS referral clinics in Sheffield, Oxford, and London. Metabolon will profile matched plasma and cerebral spinal fluid (CSF) from patients diagnosed with an MND (mostly ALS) as well as plasma and CSF from non-affected controls. "We are very excited to be collaborating with Metabolon on this important programme of work which aims to understand in detail the metabolism of cells within the nervous system, including motor neurons. ALS/MND is a cruel disease where there is a huge unmet need for better neuroprotective therapies and improved diagnostic tools. We aim to understand what goes wrong with metabolism in ALS/MND compared to healthy control participants and to identify potential pathways that can be tackled with novel therapeutic approaches. We also aim to discover metabolic biomarkers specific to different subgroups of patients with ALS/MND which may allow precision medicine approaches – targeting the right treatment to the right patient group" said Professor Dame Pamela Shaw, Director of SITraN and Professor of Neurology at the University of Sheffield, UK. "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA. Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon. "AMBRoSIA is the largest study of its kind to be funded by the MND Association and has been instrumental in taking the candidate biomarker neurofilament light into clinical trials, which shows the power of having a resource of multi-centre longitudinal collection of samples. We are delighted that the resource continues to be utilised in this new partnership driving precision medicine biomarkers discovery towards new treatments for ALS/MND", said Dr. Sophie Nyberg, Research Programmes and Partnerships Manager at the MND Association. To learn more about Metabolon's research and development efforts in neurodegenerative diseases, visit https://www.metabolon.com/applications/neuroscience/. About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is enabled by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
Brazilian Development Bank (BNDES) grants FINAME certificate to the company's solar trackers for meeting Brazil's local content requirements NORWALK, Conn., Jan. 23, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of advanced, cost-effective solar tracking solutions for ground-mounted photovoltaic (PV) plants, announced the opening of a new factory, training, service, and technical support center exclusively for its Genius Tracker™ solar trackers in Feira de Santana, Bahia, Brazil. GameChange Solar Brazil factory workers building Genius Tracker(TM) components The Brazil factory, located in Feira de Santana, Bahia, became operational in November 2023. It has the capacity to produce 2.5 GW of trackers and can be expanded to meet additional demand. In addition to serving the local market, the Brazilian factory will be able to supply Genius Tracker units to other Latin American countries. In addition, the Brazilian Development Bank (BNDES) has granted FINAME certification for its GameChange Solar Genius Tracker trackers, assuring industry customers that the trackers meet Brazil's domestic content and manufacturing process requirements. "Opening our new factory in Brazil demonstrates GameChange Solar's commitment to the Brazilian solar economy," said Vikas Bansal, International President at GameChange Solar. "As a global leader and supplier of solar tracker technology, we are thrilled to be operational, FINAME-compliant, and providing high-quality solar jobs in one of the fastest-growing solar markets in the world. We are open for business and will start fulfilling orders immediately." Ion Accosta, Operations Director & Head of Brazil at GameChange Solar, added "Having the factory and service center in addition to our business headquarters in São Paolo is such a great step for us in Brazil. We will be able to provide unparalleled service to our customers with the ability to provide in-country manufacturing, training, service, and support." According to recent forecasts by Absolar, Brazil's solar energy association, new investments in Brazil's solar PV industry could exceed BRL 38.9 billion ($7.8 billion) in 2024, with developers expected to install more than 9.3 GW of solar capacity this year. About GameChange Solar GameChange is a leading global provider of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 26 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun's movement across the sky and optimize plant performance while also protecting the array from damaging weather conditions. Additionally, GameChange Solar, through its GeniusBOS subsidiary, is growing a portfolio of products for the broader balance of system needs of solar arrays. For more information, please visit GameChange Solar. Contact:Lisa AndrewsDirector of MarketingGameChange Solarlisa.andrews@gamechangesolar.com
A12 藝術空間
2024
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)